HDBuzz-Aggregator

A new review from the University of Cambridge explores ocular biomarkers in HD, including retinal scans and eye movement tracking.Read more

⏱️ 8 min read | Your brain is an advanced supercomputer. But in HD, a core processor starts to malfunction. A research group at UCLA has taken a close look to visualize the specific circuits going haywire – and how they look different in HD.Read more

⏱️ 7 min read | Living at risk for Huntington’s disease imposes a massive psychological burden. A small interview-style study of at risk 12 people dove into how these people cope day-to-day.Read more

⏱️10 min read | Results from the VIBRANT-HD trial are now published in a peer reviewed journal. This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ultimately halting the trial.Read more

Two individuals with the same CAG repeat count can have vastly different HD journeys. A new study looking at individuals with 36-42 repeats shows that DNA sequence patterns play a major role in symptom onset and progression.Read more

⏱️ 7 min read | A team of researchers developed a simple platform to test how toxic different types of HTT protein clumps are using a laboratory worm model. They showed that certain types of clumps are harmful to the worms, while others are not.Read more

⏱️ 9 min read | January 2026 HD research recap: SKY-0515 shows promising safety data, community advocacy helps secure critical FDA meeting for AMT-130, plus new insights on sleep, vaccines, and symptom management. Read the full roundup!Read more

Skyhawk Therapeutics shared results for SKY-0515, a drug designed to lower huntingtin. The drug appeared generally safe, with 60% reduction of huntingtin in blood at the highest dose tested. This data is an encouraging step as larger trials continue.Read more

⏱️5 min read |The Huntington’s disease community's unprecedented mobilization helped secure a high-priority FDA meeting to discuss the path forward for AMT-130.Read more

⏱️6 min read | Most people with HD report sleep problems, & new research suggests sleep quality is linked to many aspects of living with the disease. Wearables tracked people with HD for a year & revealed better sleep & strength training might help.Read more

⏱️6 min read | Ever wonder when to expect the next update from a clinical trial for Huntington’s disease? The HDBuzz Trial Tracker puts future updates for HD trials on a clear timeline, with deeper explanations in our articles when you want them.Read more

A recent article in the scientific journal, Nature describes “A natural experiment on the effect of herpes zoster (shingles) vaccination on dementia”. This study makes similar conclusions to other studies worldwide, and was based on a regulatory phenomenon in Wales, UK, in which depending on a precise birth date in 1933,...Read more

UniQure announced on January 9, 2026 that they have scheduled a Type A meeting with the FDA to discuss the approval pathway for AMT-130 in the United States. Type A meetings are urgent, high-priority discussions reserved for urgent issues, and they happen fast, typically within 30 days. The meeting...Read more

Doctors have been prescribing drugs to help manage Huntington’s disease (HD) symptoms like chorea (involuntary movements) and irritability for decades. But surprisingly, there are not many studies directly comparing these medications head-to-head. A new study called Neuro-HD, published in Parkinsonism & Related Disorders, helps to fill this gap. Researchers compared...Read more

As of January 1, HDBuzz is officially out on its own! Cue your celebratory party poppers as we enter this new chapter with an excited (and nervous!) smile. After lots of preparation, planning, and behind-the-scenes work, HDBuzz has become an independent nonprofit organisation. This marks a major milestone for our...Read more

This was a year that tested the resilience of the Huntington’s disease (HD) community, with 2025 being remembered for landmark highs followed by disappointing lows shadowed in confusion. Data from clinical trials produced the strongest evidence yet that we can slow disease progression, offering families concrete hope that changing the...Read more

Huntington’s disease (HD) is caused by a repeated stretch of the genetic letters C-A-G within the huntingtin (HTT) gene above a critical number. If the repeats exceed 40, then signs and symptoms of HD will begin at some point in that person’s life, if they live long enough. The disease-causing...Read more

A new Huntington’s disease (HD) clinical trial has reached an important milestone: the first participants have now been dosed in POINT-HD, a Phase 1 study testing a new, selective huntingtin-lowering drug. RG6496 is designed to only lower levels of the expanded form of huntingtin (HTT), preserving levels of regular HTT....Read more

One mystery that many scientists think holds the key to curing HD is its mysterious age of onset. Although people with HD carry the expanded gene from birth, they generally don’t develop symptoms until later in life, suggesting something bad is brewing beneath the surface! One explanation, which has gained...Read more

Ever since large genetic studies in Huntington’s disease (HD) revealed that the longer the CAG expansion, the earlier symptoms appear, we’ve known that repeat length matters. Recent work has highlighted just how that repeat length increases within vulnerable brain cells — from about 50 CAGs to over a thousand.  ...Read more

On December 4, 2025, uniQure announced they have received the final meeting minutes from their October 29 pre-Biologics License Application (BLA) meeting with the FDA regarding AMT-130. The minutes confirm what was reported in early November: the FDA currently believes the Phase I/II data are unlikely...Read more

When it comes to thinking about the effects of Huntington’s disease (HD), most people automatically start to think about the brain due to the severe symptoms caused by the breakdown of brain cells. It’s easy to forget that the gene which causes HD is present throughout the whole body –...Read more

Depression and anxiety are common symptoms of Huntington’s disease (HD), and they can make everything harder. New research explores how sertraline, a widely-used antidepressant, affects protein production in HD cells and mice, finding that it prevents motor problems in HD mice and is linked to slower functional decline in people...Read more

Welcome back to the HDBuzz monthly research roundup! November was a busy month, with new developments in everything from gene therapy and stem cells to DNA repair, genetic modifiers, and protein folding. Here’s a friendly guide to what scientists learned this month, why it matters, and what it might mean...Read more

Imagine a busy clothing factory. Proteins are like newly sewn shirts coming off the machines. They’re floppy, wrinkled, and can create a giant mess if they’re left unfolded. Normally, the cellular clothing factory employs “chaperone proteins” that act like skilled pressers. They grab each shirt, apply energy from a hot...Read more

SOM3355 is an investigational therapy aimed at managing multiple symptoms of Huntington’s disease (HD) and recently crossed two key regulatory milestones. In September, the European Medicines Agency (EMA) issued a positive opinion supporting orphan drug designation for SOM3355. Now, following a productive End-of-Phase-2 meeting in the United States, the US...Read more

Scientists often use genetics, the study of DNA, to understand the cellular changes that cause disease. By comparing people’s DNA with their symptoms, they can pinpoint specific genetic differences, called variants, that influence the severity of a disease. Huntington’s disease (HD) is well-suited for genetic analysis because of its well-understood...Read more

Our bodies are experts at looking after our DNA and are continuously monitoring for any damage that needs to be repaired to keep us healthy. Parts of DNA that are very repetitive, like the sequence causing Huntington’s disease (HD), are very tricky to look after and our body can try...Read more

A small study from Brazil tested whether stem cells from human dental pulp, the soft tissue inside teeth, could help people with Huntington’s disease (HD). The results hint at small improvements on some movement measures, but the study had few participants who were tracked over a short timeframe, and many...Read more